Objective. For patients with systemic lupus erythematosus (SLE) who are at risk of diseaserelated mortality, we have initiated a protocol of intensive immunosuppression and haematopoietic stem cell support. The first patient enrolled in this study was in the midst of a lupus flare manifest by nephritis and rapidly declining renal function, uncontrolled hypertension, immune-mediated cytopenias, and serositis characterized by a large pericardial effusion and abdominal pain. Antinuclear antibody (ANA), anti-double-stranded (ds) DNA and complement were abnormal. This patient is now more than 1 yr post-stem cell transplant and is taking no immunosuppressive medication. Her serologies are normal, effusions have resolved, blood pressure is normal and renal function is markedly improved. The clinical and serological course of this patient is summarized here.
Anecdotal case reports describe individuals undergoing than autologous transplantation, leading consensus conallogeneic haematopoietic stem cell transplantation for ferences addressing the option of high-dose therapy for haematological disease who subsequently entered durautoimmune disease to recommend the use of autologable remission of a coincidental autoimmune disorder ous stem cells [11] . Purging of lymphocytes from the [1] [2] [3] [4] [5] . Intensive immunosuppression and haematopoautograft has also been recommended since autologous ietic stem cell transplantation has, therefore, been prohaematopoietic stem cell transplantation, performed for posed as a therapy for patients with severe autoimmune patients with haematological malignancies and a coindiseases (SADS ), including individuals with systemic cidental autoimmune disorder, has been associated with lupus erythematosus (SLE) who have poor prognostic early serological and clinical relapse of the autoimmune features [6] [7] [8] [9] [10] . Allogeneic haematopoietic stem cell disease [12, 13] . We outline here the selection of the transplantation has a higher morbidity and mortality first patient treated by autologous haematopoietic stem cell transplantation, the clinical course in the year following transplant, the treatment-related toxicities and Leukapheresis using a continuous-flow blood cell sep-1. Biopsy-proven WHO class II, III or IV glomeruloarator is initiated when the rebounding white blood cell nephritis which has failed NIH short-course cyclocount ( WBC ) reaches 1000/ml (1.0 × 109/l ) and the phosphamide therapy (500-1000 mg/m2 monthly for platelet count is >40 000/ml (40 × 109/l ). Apheresis is at least 6 months), with treatment failure defined as continued daily until the number of harvested progenitor failure of serum creatinine to return to normal or cells reaches a minimum of 2.0 × 106 CD34+ cells/kg pre-exacerbation level.
body weight after CD34+ cell selection. 
Patient course Stem cell procurement (Table 1a)
Haematopoietic stem cells are mobilized with cyclophos-A 24-yr-old woman was diagnosed with SLE at age 11, when she presented with arthralgias and a malar rash. phamide and granulocyte colony-stimulating factor (G-CSF ) (Amgen, Thousand Oaks, CA, USA).
Family history was non-contributory. Since the time of her diagnosis, her haemoglobin generally had ranged of the right atrium. Bone marrow biopsy was hypercelfrom 6.5 to 7.2 mg/dl (4.03-4.46 mmol/l ), her WBC lular and showed an increase of megakaryocytes. was 2000-2400/ml (2-2.4 × 109/l ) and the platelet count Cytogenetics were normal. Over the next 2 days, before had remained at~100 000/ml (100 × 109/l ). Serum C3, initiation of treatment, the serum creatinine rose to antinuclear antibody (ANA) and anti-double-stranded 4.5 mg/dl (398 mmol/l ). (ds) DNA never achieved normal values, even during
Following peripheral blood stem cell mobilization periods of clinical remission. At 14 yr of age, the patient with cyclophosphamide, the serum creatinine increased had been hospitalized with pneumonitis, nephritis and to 5.5 mg/dl (486 mmol/l ), phosphorus increased to 7.8 bleeding secondary to immune-mediated thrombocytomeq/dl (2.5 mmol/l ) and serum bicarbonate decreased penia. She required dialysis and mechanical ventilation, to 11 mmol/l. These abnormalities occurred despite the and was treated with plasmapheresis, corticosteroids use of an oral phosphate binder and i.v. infusion of and cyclophosphamide. Over the following decade, she sodium bicarbonate. Eight days after cyclophosphamide had experienced recurrent flares of systemic lupus chardosing, the absolute neutrophil count nadired below acterized by fatigue, fever, malar rash, arthralgias, 500/ml (0.5 × 109/l ) for 2 days, at which time the abdominal pain and several episodes of lupus nephritis, abdominal pain and tenderness resolved. Reimaging of each treated with short-course NIH monthly cyclophosthe pericardial effusion showed a decrease of roughly phamide. Since diagnosis, active disease had prevented 50%. The electrolyte abnormalities gradually corrected. tapering the prednisone dose below 20 mg a day. In
Ten days after cyclophosphamide infusion, the WBC addition to cyclophosphamide, prior therapies had rose to >1000/ml (1.0 × 109/l ). Beginning that day, a included hydroxychloroquine, methotrexate and aza-20 l leukapheresis was performed daily for 3 consecutive thioprine. At age 23, the young woman had taken an days. The collected peripheral blood stem cells (PBSC ) indefinite absence from medical school after developing contained 108 T cells/kg patient weight. After CD34+ recurrence of glomerulonephritis. A biopsy obtained at cell selection, the number of T cells was diminished by that time was consistent with ( WHO) class IV glomalmost two logs (3.1 × 106 T cells/kg). The patient was erulonephritis (Fig. 1) . After five monthly courses of discharged home on day 14. cyclophosphamide (500 mg/m2), her serum creatinine After a 6 week interval, the serum creatinine stabilized transiently stabilized at 1.8 mg/dl. Several months later, at 2.5 mg/dl (221 mmol/l ). The patient was readmitted she developed transverse myelitis which responded to and high-dose cyclophosphamide (200 mg/kg over 4 high-dose corticosteroids. At that point, she was referred days) and ATG (90 mg/kg over 3 days) were administo this institution in consideration of high-dose chemotered followed by a 3 day rest before reinfusion of therapy with stem cell support.
CD34+-enriched stem cells. G-CSF (5 mg/kg/day) was Upon referral, the patient exhibited active lupus with begun the following day. Following cyclophosphamide a malar rash, arthralgias, uncontrolled hypertension of infusion, the patient again experienced hyperphos-230/130 mmHg, rapidly declining renal function, and phataemia, hyperuricaemia, normal anion gap metabolic serositis manifest as diffuse abdominal pain and abdomacidosis, and a rising serum creatinine despite prophyinal distention secondary to ascites. Laboratory values laxis with allopurinol and alkaline hydration. Owing to are included in Table 2 . The measured creatinine clearhyperphosphataemia, dialysis was performed on two ance was 28 cc/min. Echocardiographic evaluation occasions 8 days apart. Neutrophil recovery, defined as revealed a large pericardial effusion causing invagination an absolute neutrophil count >500/ml (0.5 × 109/l ), occurred on day 10. The platelet count rose to >20 000/ml (20 × 109/l ) without transfusion by day 14. During the period of neutropenia, low-grade fever (100.5°F ) developed. Blood cultures grew Staphylococcus epidermidis. The empirical broadspectrum antibiotic coverage begun for neutropenic fever included pipercillin/tazobactam, ciprofloxacin, vancomycin and lipid-formulation amphotericin. The patient was discharged home on day 14 .
Laboratory values by day 60 after stem cell reinfusion had improved or normalized ( Table 2) , and the patient had no evidence of active disease with an SLE Disease Activity Index (SLEDAI ) score of zero. The rash, arthralgias, abdominal pain, and pericardial and pleural effusions fully resolved. At 1 yr follow-up, this patient remained in clinical remission ( fever. Since lupus may include central nervous system Discussion vasculitis, and since renal involvement may be associated The immunosuppressive regimen used for this approach with hypertension, there is an increased risk of a serious is based on a standard conditioning regimen in use for intracranial bleed during the interval of thrombocytoallogeneic transplantation of aplastic anaemia. The penia. This potential complication was avoided by conpathogenesis of aplastic anaemia is often due to immunetrol of the blood pressure and prophylactic transfusion mediated suppression of haematopoiesis and may be of platelets. treated with either immunosuppression or allogeneic
In this patient, high-dose cyclophosphamide and ATG transplantation. Some patients with aplastic anaemia resulted in clinical and serological remission of active undergoing allogeneic transplantation have rejected their and refractory disease for the first time since its onset sibling's graft and subsequently reconstituted normal 13 yr ago. Specifically, this is the first time since disease endogenous haematopoiesis. This suggests that maximal onset that complement levels are normal and anti-ds suppression of an autoimmune disease even without a DNA is negative. Interestingly, the patient's hypertensource of new stem cells may cure the disease. It also sion, which had been difficult to control, requiring four highlights that this regimen is not myeloablative. The different antihypertensive drugs, gradually subsided. reason why CD34+ stem cells are reinfused is to shorten Although remission has persisted for longer than 1 yr, the duration of severe neutropenia and thrombocytoresponse durability is unknown. The relapsing and penia in order to decrease the risk of serious infection remitting nature of lupus makes definition of a complete and bleeding.
remission difficult, and no agreed upon medical definiMobilization of stem cells and immune ablation with tion for a complete remission exists in SLE. We cannot, high-dose cyclophosphamide was relatively uncompliconsequently, document 'complete remission'. However, cated. The patient did not develop a fever or require there has been no evidence of active disease since antibiotics during mobilization. Subcutaneous G-CSF transplantation and anti-ds DNA and complement have did not exacerbate the manifestations of lupus. In fact, returned to normal. Furthermore, since the mechanwithin days of undergoing mobilization with cyclophosism(s) of transplant-associated remission remains phamide, and while on G-CSF, clinical symptoms subunclear, it is possible that a similar long-term outcome sided. A cell lysis-like effect did occur following each would occur without reinfusion of haematopoietic treatment with cyclophosphamide. Renal insufficiency is stem cells. usually a contraindication to stem cell transplantation Based on experience with T-cell-depleted autologous for haematological malignancies and electrolyte evidence haematopoietic transplantation in patients with maligof cell lysis in patients with haematological diseases who nancy, the redeveloping immune system can be expected are in remission at the time of transplantation is unusual.
to have an immunosuppressed phenotype with diminIn contrast, renal involvement is common in SLE and ished responses to mitogens and a low CD4+ cell count is one of our criteria for transplantation. In these for~12 months following transplantation [14, 15] . patients, high-dose chemotherapy may cause a cell lysis Recovery of immunity may be due to pre-thymic CD34+ effect and the possibility of early dialysis should be progenitor cell differentiation resulting in recapitulation anticipated.
of lymphocyte ontogeny. Alternatively, immunity may Another potential complication anticipated in this arise by peripheral expansion of post-thymic T lymphopatient was an increased risk of fungal infections from cytes that either survived conditioning or were reinfused chronic steroid dependence. We therefore started a renalsparing lipid formulation of amphotericin with the first with the graft [16 ] . Pre-thymic vs post-thymic derivation of T cells following transplantation may be important patients have shown identical TcR a and b chain sequences. These autoimmune T-helper cells of lupus for remission duration. Predominance of the post-thymic pathway may allow for expansion of pre-existing diseasepatients have been shown to respond to charged epitopes in various DNA-binding nucleoproteins [21] . Defective mediating lymphocytes. However, it also remains uncertain whether immunity re-emerging from a pre-thymic suppresser function may contribute to this autoreactive T-helper cell population. In human peripheral blood pathway will result in self-tolerance.
Purging the graft of lymphocytes by CD34+ selection mononuclear cells, NK-derived transforming growth factor beta ( TGF-b) induces suppresser activity in may increase the likelihood that post-transplant immunity will arise from pre-thymic differentiation from CD8+ cells in conjunction with interleukin (IL)-2 [22] . Gray et al. [23] found that the NK cells of SLE patients CD34+ stem cells. When compared to non-selected grafts, CD34-enriched grafts have a more prolonged are defective in their production of active TGF-b and that the normal T-cell autoregulatory circuit in which T-cell recovery interval [17] . The CD4/CD8 ratio is inverted (<1.0) for up to 1 yr after autografting. When CD8+ cells limit CD4+ cell expansion and activation is faulty. Evidence that a CD34-selected graft favours compared to an unselected graft, CD34-selected cells have an absolute number of CD4+ T-helper cells that reconstitution of the V b repertoire by naive cells and that NK cells are increased in the early post-transplant remains significantly lower at 1 yr. For the first 2 months after transplantation, the CD4+ T-cell population period indicates that immune ablation followed by stem cell transplantation may promote an early 'tolerogenic consisted predominantly of CD45RO+ helper/memory cells. It remains unclear whether the helper memory environment'. (CD4/CD45RO+) lymphocytes survived the conditioning regimen or were reinfused with the graft. By 3 Summary months after transplantation, the absolute number of CD4/CD45RA+ (helper/naive) cells begins to increase.
Several centres in Europe and America are initiating It is also unknown whether CD45RA+ naive lymphohaematopoietic transplantation protocols for autocytes arise by pre-thymic maturation from CD34+ immune diseases. We are aware of one other centre that haematopoietic progenitor cells or by expansion of prehas performed stem cell transplantation in a patient existing or reinfused post-thymic CD45RA+ cells.
with lupus which was quiescent at the time of transplant In haematological diseases, the T-cell receptor ( TcR) [24] . Enthusiasm for this approach is slowed by recognirepertoire after CD34-selected haematopoietic transtion that autoimmune diseases have diverse clinical plantation demonstrates diminished diversity of V b TcR progressions, which may include an isolated episode expression [17] . Following transplantation for haematowithout residual damage, an indolent progression with logical diseases, significant post-transplant expansion of or without significant disability, or a rapid progression specific TcR populations was observed in all patients with early mortality. Intensive immune suppression and transplanted with a CD34-enriched graft at one institustem cell transplantation has significant potential for tion, showing an apparently random overexpression of infectious and regimen-related side-effects and should, various V b TcR subsets, beginning as early as 3 weeks therefore, be reserved for patients with severe disease and persisting as late as 1 yr after bone marrow transwho have failed conventional therapy. plantation (BMT ) [17] . A comparison to pre-transplant TcR subsets showed that while several V b
TcR subsets which had been present in their patient population at
